Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Fulcrum Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Fulcrum Therapeutics' CEO'su Alex Sapir, Jul2023 tarihinde atandı, in görev süresi 1.25 yıldır. in toplam yıllık tazminatı $ 7.36M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5% maaş ve 95% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.31% ine doğrudan sahiptir ve bu hisseler $ 690.30K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.9 yıl ve 7.8 yıldır.

Anahtar bilgiler

Alex Sapir

İcra Kurulu Başkanı

US$7.4m

Toplam tazminat

CEO maaş yüzdesi	5.0%
CEO görev süresi	1.3yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	1.9yrs
Yönetim Kurulu ortalama görev süresi	7.8yrs

Son yönetim güncellemeleri

Recent updates

Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%

Sep 13

Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly

Sep 12

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Jul 12

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Feb 11

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Oct 28

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Jul 11

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Nov 17

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Oct 18

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13

Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M

Aug 11

Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave

Jul 11

Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder

Jul 05

Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling

Jun 27

These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

May 10

Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Apr 09

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Dec 09

Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point

Sep 03

Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

Aug 12

News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Aug 11

CEO Tazminat Analizi

Alex Sapir'un ücretlendirmesi Fulcrum Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$20m
Mar 31 2024	n/a	n/a	-US$99m
Dec 31 2023	US$7m	US$369k	-US$97m

Tazminat ve Piyasa: Alex 'nin toplam tazminatı ($USD 7.36M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: Alex şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Alex Sapir (57 yo)

1.3yrs

Görev süresi

US$7,360,015

Tazminat

Mr. Alexander C. Sapir, also known as Alex, serves as Chief Executive Officer, President and Director at Fulcrum Therapeutics, Inc. since July 01, 2023. Mr. Sapir has been Director at PhaseBio Pharmaceutic...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alexander Sapir	CEO, President & Director	1.3yrs	US$7.36m	0.31% $ 700.0k
Alan Musso	Chief Financial Officer	1.2yrs	US$2.15m	0% $ 0
Curtis Oltmans	Senior VP	3.9yrs	US$2.32m	0.016% $ 35.2k
Mel Hayes	Executive Vice President of Patient Experience	less than a year	US$2.19m	0.011% $ 24.2k
Bradley Bernstein	Founder	no data	Veri yok	Veri yok
Michael Green	Founder	no data	Veri yok	Veri yok
Rudolf Jaenisch	Founder	no data	Veri yok	Veri yok
Tsun-Huei Lee	Founder	no data	Veri yok	Veri yok
Danny Reinberg	Founder	no data	Veri yok	Veri yok
Gregory Tourangeau	Controller & Principal Accounting Officer	2.6yrs	Veri yok	0.016% $ 36.0k
Jeffrey Jacobs	Chief Scientific Officer	1.9yrs	Veri yok	Veri yok
Kim Hazen	Chief People Officer	3.9yrs	Veri yok	Veri yok

1.9yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim: FULC 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alexander Sapir	CEO, President & Director	1.3yrs	US$7.36m	0.31% $ 700.0k
James Arthur Geraghty	Independent Director	8.3yrs	US$131.90k	0.15% $ 328.4k
H. Sweeney	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
James Collins	Independent Director	7.8yrs	US$123.31k	0.038% $ 85.3k
Katina Dorton	Independent Director	4.8yrs	US$136.40k	0% $ 0
Leslie Leinwand	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Gould	Director	8.3yrs	US$724.50k	0.80% $ 1.8m
Alan Ezekowitz	Independent Director	7.8yrs	US$131.40k	0.046% $ 104.7k
Kathryn Haviland	Independent Chair of the Board	6.3yrs	US$157.90k	0% $ 0
Jeffrey Statland	Member of FSHD Clinical Advisory Board	no data	Veri yok	Veri yok
Rabi Tawil	Member of FSHD Clinical Advisory Board	no data	Veri yok	Veri yok
Baziel van Engelen	Member of FSHD Clinical Advisory Board	no data	Veri yok	Veri yok

7.8yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: FULC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

Fulcrum Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Fulcrum Therapeutics, Inc. Announces Executive Appointments

Fulcrum Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Fulcrum Therapeutics, Inc. Announces Executive Changes

CEO, President & Director recently bought US$492k worth of stock

Fulcrum Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer, Effective August 7, 2023

Fulcrum Therapeutics, Inc. Chief Executive Officer Changes

Recent updates

Fulcrum Therapeutics, Inc. Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%

Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly

Fulcrum Therapeutics, Inc. Announces Executive Appointments

Fulcrum Therapeutics, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Consensus revenue estimates increase by 1,613%

Price target increased by 7.5% to US$14.25

First quarter 2024 earnings released: US$0.43 loss per share (vs US$0.41 loss in 1Q 2023)

Fulcrum Therapeutics, Inc. Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (ReDUX4) in The Lancet Neurology

Fulcrum Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Fulcrum Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Fulcrum Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 24%

CEO, President & Director recently bought US$492k worth of stock

Consensus revenue estimates fall by 15%

Fulcrum Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Fulcrum Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.8% to US$11.21

Fulcrum Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

New major risk - Share price stability

Price target increased by 31% to US$10.57

Fda Lifts Clinical Hold on Fulcrum Therapeutics' Ftx-6058 for Sickle Cell Disease

Consensus revenue estimates increase by 11%

Fulcrum Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer, Effective August 7, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Value Index

Levi & Korsinsky, LLP Notifies Fulcrum Therapeutics, Inc. Investors of Class Action Lawsuit and Upcoming Deadline

Consensus revenue estimates decrease by 31%, EPS upgraded

Fulcrum Therapeutics, Inc. Chief Executive Officer Changes

Price target decreased by 22% to US$7.56

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 17% to US$18.75

Price target increased by 11% to US$24.38

Insufficient new directors

President notifies of intention to sell stock

Fulcrum Therapeutics, Inc. Announces Resignation of Bryan Stuart from the Board of Directors

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Consensus forecasts updated

Price target decreased to US$25.29

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulcrum Therapeutics, Inc. Announces Management Changes

Fulcrum Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Fulcrum Therapeutics, Inc. Announces Resignation of Judith A. Dunn as President, Research and Development

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 Redux4 Study

Price target increased to US$30.71

Consensus revenue estimates fall by 17%

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Fulcrum Therapeutics, Inc. Promotes Mel Hayes to the Chief Operating Officer

Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M

Fulcrum Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Fulcrum Therapeutics Announces Executive Changes

Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave

Fulcrum Therapeutics, Inc. Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy

Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder

Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling

Fulcrum Therapeutics Announces Proof-Of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1B Trial

Price target decreased to US$30.25